Implementation of the project “Development of an innovative personalized service – combined therapy in patients with advanced, non-resective, progressive neuroendocrine cancers”
The project includes industrial research and development and pre-implementation work aimed at developing a highly specialised personalised combined treatment service consisting of PRRT and CAPTEM in patients with advanced progressive neuroendocrine tumours (NEN).
The project assumption is based on the synergy of PRRT and CAPTEM, based on clinically detailed data, with PRRT dose modification based on individual dosimetric measurements. One of the key elements will be to assess the usefulness of molecular markers of response to the therapy, using specific gene transcripts. Especially the aspect of the possibility of early response identification will be analyzed in industrial studies based on the assessment of gene transcripts. Another issue will be the development of personalized internal dosimetry, based on dose estimation based on the diagnostic test with SRS and its verification together with the assessment of internal dosimetry based on the postoperative examination performed after the first dose of PRRT.
The development work assumes verifications of previously developed therapy algorithms, performed in two parallel groups of patients, depending on the position of primary lesion, “pancreatic” group – comparison of standard CAPTEM therapy, second (intestinal) group – PRRT compared to the proposed combined therapy. The personalised therapy service with the evaluation and analysis of a specific panel of gene transcripts, based on the molecular response to the proposed treatment, is of paramount importance in the identification and understanding of the early response to the combination therapy, together with the optimisation of the proposed personalised combination therapy service and potential avoidance of adverse effects, or change of therapy in the absence of its effects.
Project value: 7 164 146.98 PLN
The value of the European Funds’ contribution: 4 830 325,93 PLN
